Foresite Capital Management IV’s Ascendis Pharma A/S ASND Stock Holding History

Foresite Capital Management IV’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-68,981	Closed	-$9.6M	–	14
2019 Q4	$9.6M	Sell	68,981 -176,443	-72%	-$19.6M	4.14%	9
2019 Q3	$23.6M	Hold	245,424	–	–	7.64%	5
2019 Q2	$28.3M	Hold	245,424	–	–	7.99%	3
2019 Q1	$28.9M	Hold	245,424	–	–	10.38%	3
2018 Q4	$15.4M	Hold	245,424	–	–	7.06%	6
2018 Q3	$17.4M	Sell	245,424 -25,000	-9%	-$1.72M	5.7%	10
2018 Q2	$18M	Sell	270,424 -204,995	-43%	-$13.5M	6.13%	9
2018 Q1	$31.1M	Sell	475,419 -53,924	-10%	-$3.03M	12.89%	2
2017 Q4	$21.2M	Buy	+529,343	New	+$19.2M	14.86%	2

Other funds holding ASND

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Foresite Capital Management IV's ASND Position: Q1 2020 in Review

Foresite Capital Management IV sold out of Ascendis Pharma A/S (ASND) in Q1 2020, closing a stake of 68,981 shares — an estimated $9.6M sold.

Foresite Capital Management IV first reported a position in ASND in Q4 2017 and held it in 9 quarters. The position peaked at $31.1M in Q1 2018. 147 funds tracked by Wall St. Rank hold ASND as of Q1 2020.

Foresite Capital Management IV reported no remaining Ascendis Pharma A/S position as of Q1 2020 after selling out during the quarter.
Foresite Capital Management IV sold 68,981 Ascendis Pharma A/S shares in Q1 2020, an estimated $9.6M.
Foresite Capital Management IV first reported a position in Ascendis Pharma A/S in Q4 2017 and held it in 9 quarters.
Foresite Capital Management IV's Ascendis Pharma A/S position peaked at $31.1M in Q1 2018.
147 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2020.

Based on Foresite Capital Management IV's 13F filing for Q1 2020, filed 14 May 2020.